Programs of work at the laboratory range across the Company"s development portfolio of trojan anti-cancer drugs and anti-cancer-stem-cell drugs. These include: protein engineering and associated molecular biology involving recombinant fusion proteins of trojan peptides linked to various proteins, laboratory scale protein production and purification from either bacteria or mammalian cells, the administration of the proteins to cultured cells and to animals to test pharmacokinetics and efficacy.
We have the following product candidates in the pre-clinical stage of development:
- TR1, Antennapedia-P21: A novel recombinant fusion protein which delivers the p21 protein to the cell nucleus and, in combination with conventional chemotherapy, achieves tumor eradication and increases survival in animals. Clinical development of the product has commenced.
- TR2, Antennapedia-P53: A novel recombinant fusion protein which aims at delivering pan-cancer therapy. It is currently manufactured and tested in cultured cells and animal models.
- TR3, Antennapedia-Numb: Numb is a well known negative regulator of the Notch pathway. We are developing a novel approach to Notch inhibition using the Antennapedia‑Numb fusion protein which targets the pathway in existing tumors. Clinical development of the product will follow.
- TR4, Antennapedia-Mastermind: A novel approach to Notch inhibition using the truncated version of Mastermind‑like protein (MAML) that behaves in a dominant‑ negative (DN) fashion and inhibits Notch activation. An Antennapedia‑DN/MAML fusion protein has been created that targets the pathway in existing tumors. Clinical development of the product will follow.